Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

In this observational study, blood samples will be collected from adult and pediatric patients with CGD. The level of circulating adenovirus antibodies and inflammatory cytokines will be measured to characterize the prevalence of these markers in this population.

Primary outcomes

• Total adenoviral-specific antibody (TAb) titer [1 Day]: Level of total adenoviral-specific antibody in blood
• Adenoviral-specific neutralizing antibody (NAb) titer [1 Day]: Level of adenoviral-specific neutralizing antibodies in blood

Secondary outcomes

• Circulating inflammatory cytokine levels [1 Day]: Level of inflammatory cytokines in blood

Sex: All

Inclusion Criteria:

* The participant must have been diagnosed with CGD based on the referring physician's confirmation that NADPH oxidase activity is ≤5% (i.e., the percentage of dihydrorhodamine-positive \[DHR+\] cells is ≤5% by flow cytometry) OR based on confirmed pathogenic mutation in a CGD associated gene (CYBB, CYBA, NCF1, NCF2, NCF4, or CYBC1).
* The participant or the participant's legally authorized guardian or representative (if applicable) must be capable of giving signed informed consent.
* The participant (with assistance from the participant's legally authorized guardian/representative or primary caregiver, if applicable) must be capable of complying with the requirements and restrictions listed in the protocol and informed consent form (ICF).

Exclusion Criteria:

* The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
* The participant is unable to comply with the sample collection procedure based on investigator judgment.

• Results publication: Morna Dorsey, Claire Booth, Jonathan Cotliar, Esther Shamir, Mansi Purwar, Patrick Au, Chris Plescia, Andrew Dietz, Siobhan Burns; Cytokine Profile in Patients with Chronic Granulomatous Disease (CGD). J Hum Immun 1 May 2026; 2 (CIS2026): eCIS2026abstract.45. doi: https://doi.org/10.70962/CIS2026abstract.45
• Results publication: Claire Booth, Morna Dorsey, Jonathan Cotliar, Esther Shamir, Patrick Au, Chris Plescia, Siobhan Burns, Andrew Dietz; Preexisting Antibodies to Virus-Like Particles (VLP) Derived from Helper-Dependent Adenovirus (HDAd) in Patients with Chronic Granulomatous Disease (CGD). J Hum Immun 1 May 2026; 2 (CIS2026): eCIS2026abstract.88. doi: https://doi.org/10.70962/CIS2026abstract.88